More than 10 years into this bull market, Buy and Outperform analyst ratings generally come with implied upside potential of 8% to 10%. However, the author of today’s article notes that “One area of the market that can see much greater upside opportunities, which also implies a greater risk, is the biotech and emerging pharmaceutical stocks” – and he proceeds to highlight 20 biotech and pharma stocks that have seen analyst calls since January 1st that suggest much larger upside potential. For more, CLICK HERE.
Halloween is over and assorted monster costumes have been put away – but there is still monster growth to be had in certain stocks! Today’s article highlights three stocks “with strong monster growth narratives” – each of which has recently reported impressive earnings numbers and had their price targets increased by some of Wall Street’s top-performing analysts as a result. For these three “monster growth” stocks – all of which have “Strong Buy” consensus ratings and upside potential above 20% – CLICK HERE.